Tag Archives: HRT

Medical, Research, Science

Research suggests HRT can boost brain health

HORMONE REPLACEMENT THERAPY

TAKING hormone replacement therapy (HRT) to cope with the menopause may benefit the brain and stave off memory loss, new research suggests.

A seven-year study has found women who take HRT experience fewer age-related changes to the brain.

Detailed scans suggest HRT may help preserve the structure of the prefrontal cortex, that part of the brain linked to memory and thinking.

The US researchers also found women taking the treatment had lower accumulations of amyloid plaques, toxic proteins linked to Alzheimer’s disease.

Dr Kejal Kantarci, of the Mayo Clinic in Rochester, said: “We found one form of menopausal hormone therapy taken soon after menopause may preserve brain structure in the portion of the brain responsible for memory and thinking skills.

“It may also reduce the development of amyloid plaques that can… lead to memory loss.”

The menopause, which commonly strikes women in their late 40s and early 50s, can cause symptoms including hot flushes, headaches and night sweats. HRT tackles these by providing oestrogen as the body stops producing it.

But the recently released research suggests that the treatment may also benefit the brain.

Experts believe this is because oestrogen can protect the connections in the brain when natural hormone production stops, this protection disappears. Replacing it artificially could restore protection.

The findings are significant because many women go without HRT after studies in the early 2000s raised fears of side effects. The new paper, published in the medical journal Neurology, reports on research involving 75 healthy women with an average age of 53 who had gone through the menopause within the previous three years.

Twenty women were given HRT pills, 22 received HRT patches and 33 received placebo pills or patches that contained no hormones. The women were kept on the treatment for four years, then tracked for a further three years after the therapy ended. They had MRI brain scans every few months.

The researchers found that in those on HRT patches, there was less shrinkage in the dorsolateral prefrontal cortex – a part of the brain that assists with memory, thinking, planning and reasoning. There were also lower accumulations of amyloid plaques among these women.

Those on HRT pills did not experience as much benefit while taking the therapy, but when they stopped a difference started to appear.

There was no difference between HRT treatment and placebo in thinking and memory tests, but the scans suggest that HRT influenced the structure of the brain and, that over a longer period, a difference might be seen.

Dr Sara Imarisio, of Alzheimer’s Research UK, said: “This small study found no link between HRT and memory and thinking, but women who had taken the hormone estradiol via skin patches showed some signs of better brain health.

“More studies are needed to piece together the effect of hormones on the brain and how different forms of hormone therapy might impact brain health in later life.”

. Appendage 

 

Standard
Health, Medical, United States

A new study finds that HRT does not affect a woman’s memory…

Women taking hormone replacement therapy following the menopause are not at a higher risk of developing dementia, a new study has found.

HRT, which is used to treat menopausal symptoms, including hot flushes, has previously been linked with memory deterioration and a doubling of the risk of developing dementia.

Researchers followed a group of more than 1,300 women between the ages of 50 and 55 who were on HRT medication known as conjugated equine oestrogens (CEOs).

The researchers, based at the Women’s Health Centre of Excellence for Research at Wake Forest School of Medicine in Winston-Salem, North Carolina, gave one set of women placebos and one the HRT treatment. The results were studied after seven years.

They found no overall differences in the brain function scores between women taking the HRT treatment and the placebos.

Dr Mark Espeland, a professor of biostatistics, led the research programme, and said it proved giving the hormones at an earlier age of the menopause provided more benefits than prescribing them at a later stage.

Dr Espeland said:

… Our findings provide reassurance that CEO-based therapies when administered to women earlier in the postmenopausal period do not seem to convey long-term adverse consequences for cognitive function.

The researchers did note some minor speech disturbances in some of the women taking CEOs longer-term. But they attributed that to ‘chance’ and reported that it was not statistically significant.

Around 1.5 million British women use HRT, which relives symptoms of the menopause including hot flushes and mood swings by replacing the body’s declining supply of the hormone oestrogen.

Previously, studies claimed the risk of suffering from mental decline could be doubled by taking hormone replacement therapy. A warning in 2003 was given by scientists in the United States who sought to determine if healthy women should turn to HRT to combat ill-health in later life, not just menopausal symptoms.

It is believed that fewer than 3 per cent of women in the UK aged 65 and over are on the therapy.

The research was published in the medical journal, JAMA Internal Medicine.

Standard
Health, Medical, Research, Science

HRT and the menopause: benefits now thought to outweigh risks…

After more than a decade of controversy, medical experts say that Hormone Replacement Therapy (HRT) for women in their 50s is safe in combating the menopause.

Taking medication to reduce the symptoms of the menopause is now deemed safe and the benefits for women on HRT are now thought to far outweigh the potential risks. Freshly released guidance from the British Menopause Society (BMS) has sought to reassure patients.

Medical experts say hundreds of thousands of women have suffered unnecessarily as a result of the decade-long controversy over the effects of HRT.

They say that General Practitioners (GPs) should prescribe the treatment to any woman who has unpleasant menopausal symptoms, such as hot flushes and mood changes. HRT is also known to provide bone protection in later life.

However, the debate over HRT use is likely to rage on as The Royal College of Obstetricians and Gynaecologists continues to advise HRT prescription only for women with serious menopausal symptoms ‘for the shortest time possible’.

After a period of five years doctors are not expected to continue prescribing HRT medication without discussing potential risks with their patients.

Uptake of HRT halved after two studies linked it to an increased risk of heart disease and breast cancer. An estimated one million women in the UK stopped having the treatment.

But the emerging consensus now is that the benefits of HRT outweighed the risks for most women, and that GPs should consider the updated BMS advice when treating the condition.

Consultant Endocrinologist Dr Helen Buckler, from the University of Manchester, speaking at the Cheltenham Science Festival, said the two studies linking HRT to breast cancer and heart disease were ‘scientifically unreliable’.

She said:

… The new advice is HRT should be used for a slightly wider age, if need be. If a woman has symptoms affecting the quality of her personal or professional life, then the benefits outweigh the risk.

The scare of taking HRT began in 2002, when the US Women’s Health Initiative study was halted some three years early because researchers claimed women using HRT were at a higher risk of breast cancer, heart disease and strokes. Yet, this contradicted previous (and later) research which suggested its use guarded against heart problems.

HRT is normally prescribed to menopausal women in their 50s, but according to the WHI study it was also given to women in their 60s and 70s who had gone through the menopause more than a decade earlier.

Shortly afterwards the UK Million Women Study, part funded by Cancer Research, a charity, said HRT doubled breast cancer risk, but a review in 2012 said it was ‘unreliable and defective’.

The advice from Cancer Research remains that there is still convincing evidence that women who take HRT have an increased risk of breast cancer. Dr Buckler, though, said the organisation was ‘out of step’ and its approach had tended to ‘put women off’ taking the treatment.

Some younger doctors have never prescribed HRT because they assume the risks outweigh the benefits.

Cancer Research UK said there was ‘convincing evidence’ that women who take HRT have an increased risk of breast cancer, but says that risk returns to normal around five years after the medication is stopped being used.

The BMS guidance is also opposed to the ‘arbitrary’ five year limit on treatment, and says it should be continued if symptoms persist.

The BMS, a registered charity and medical foundation, receives no government funding. Its medical advisory council comprises leading international experts in post reproductive health management, who regularly draw up guidelines for health professionals.

Standard